About

About IBEX Therapeutics SA Ibex Therapeutics is Swiss biotech company developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis, debilitating conditions which very often occur as adverse effect of cancer chemo- and radiotherapy and affects the care journey and the quality of life of cancer patients. A de-risked and short path to registration and commercialization by 2028, as validated by the German health authority BfArM: the lead product (containing 2 water-based plant extracts) is produced in GMP conditions and has confirmed its efficacy and safety in a pilot study in cancer patients. Ibex Tx is raising CHF 3 million, of which 1.0+ million has already received soft commitments, with the largest part of the proceeds to fund a final pivotal clinical study, and some portfolio extensions (including a probiotic to synergize with the oral topical therapy, and a spray presentation to augment portability and convenience of use by ambulatory patients). Strong market fundamentals: sustained medical need (increasing incidence of cancer and use of mucositis-inducing therapies), and absence of reference treatment. Further, Ibex Tx will register the product in several geographies (EU, USA, Asia, BRICS), and sign licensing agreements to ensure efficient commercialization outside of Switzerland.